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Abstract
Background The diagnosis of congenital hypopituitarism
is difficult and often delayed because its symptoms are
nonspecific.
Aim To describe the different clinical presentations of
children with congenital hypopituitarism to reduce the time
for diagnosis and to begin a precocious and appropriate
treatment.
Study design We analyzed a cohort of five children with
congenital hypopituitarism, describing their clinical, bio-
chemical and radiological characteristics from the birth to
diagnosis.
Results As first sign of the disease, all of five patients
presented a neonatal hypoglycemia, associated in four
cases with jaundice. In all these four cases, the clinicians
hypothesized a metabolic disease delaying the diagnosis,
which was performed in only two cases within the neonatal
period. In the other three cases, the diagnosis was formu-
lated at 2, 5 and 8 years of life because there was severe
and precocious growth impairment.
Conclusions It is important to suspect congenital hypo-
pituitarism in the presence of persistent neonatal hypo-
glycemia associated with jaundice and of a precocious and
severe reduction of the growth velocity in childhood. In all
these cases, it is necessary to undertake a hypothalamic–
pituitary magnetic resonance imaging scan as soon as
possible, and to start appropriate treatment.
Keywords Congenital hypopituitarism  Hypoglycemia 
Neonatal jaundice  Growth impairment
Introduction
Congenital hypopituitarism is a rare condition, present
from birth, characterized by the underproduction of one or
more pituitary hormones [1]. Diagnosis is often delayed
because its clinical presentation ranges from absent to
severe non-specific symptoms, and current laboratory tests
lack sensitivity during the neonatal period. In particular,
symptoms include hypoglycemia, which may sometimes
result in a sometimes life-threatening neonatal emergency,
with seizures, apnea and cyanosis; prolonged jaundice
(with elevation of both conjugated and unconjugated bili-
rubin); dysmorphic feature with midline defects, ocular and
craniofacial anomalies; and microphallus in males, often
with undescended testes [2–4]. Birth size and weight are
normal or moderately reduced, but they rapidly decrease
with an important reduction in length in the first months of
life [5]. In some cases, newborns may be initially asymp-
tomatic but at risk of developing pituitary hormone defi-
ciencies over time [2]. In all cases, careful evaluation of
these patients is necessary to prevent the morbidity and
mortality associated with untreated hormonal abnormalities
[5–8]. However, hormonal assessment in the neonatal
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period is difficult; in fact, age-correlated normative data are
lacking at this age when contraindications are detected for
some GH provocative tests [2, 9]. The main investigation
necessary to achieve a definitive diagnosis is the magnetic
resonance imaging (MRI) of the brain and the pituitary
gland. It is helpful to research the etiology of hypopitu-
itarism and any possibly associated structural anomalies
[10]. Children with congenital hypopituitarism typically
present the classic triad of pituitary stalk (PSA) interrup-
tion syndrome: an interrupted or thin PSA, an absent or
ectopic posterior pituitary (EPP), and anterior pituitary
hypoplasia or aplasia [11, 12]. Associated abnormalities
may include optic nerve hypoplasia, absent septum pellu-
cidum, agenesis of the corpus callosum, septo optic dys-
plasia and Arnold–Chiari I malformation [10]. Moreover,
children with hypothalamic–pituitary structural abnormal-
ities more frequently have severe phenotypes and multiplex
pituitary hormonal deficiencies (MPHD) [13–16].
Most cases of congenital hypopituitarism are sporadic,
but genetics may play a role [2]. Given that our knowledge
of the genes that direct pituitary development or hormone
production is continuously expanding, an increasing pro-
portion of cases can be attributed to a specific genetic
defect. The likelihood of finding mutations is increased by
positive family histories and by association with a signifi-
cant malformation of the pituitary gland [17]. In these
cases, genetic analysis should be taken into account to
reach a definitive diagnosis.
This brief report aims to evaluate in detail the clinical
presentation of a cohort of five children with congenital
hypopituitarism to draw attention to the warning symp-
toms, and consequently, to allow for a more rapid diagnosis
and more effective treatment.
Patients
One patient was born in Verona, four in other peripheral
hospitals in the Veneto region (Italy). All five children
were referred to the Pediatric Division of the Hospital of
Verona, Italy, for diagnosis, treatment and follow-up of
their clinical condition. The study was conducted in com-
pliance with the terms of the Helsinki II Declaration.
Moreover, all parents of children gave their informed
consent to the inclusion of their children in the manuscript.
The clinical, biochemical and radiological characteris-
tics of all five patients are summarized in Table 1.
Patient 1
This patient was a female newborn of African origin. She
was born at term by vaginal delivery after an uneventful
pregnancy. The parents were not related. Apgar score was
8 at the 1st min and 10 at the 5th min. She had no sign of
perinatal distress. Birth weight was 2,700 g (-1.23 SD),
length 49 cm (-0.22 SD) and cranial circumference
33.2 cm. She did not present evident dysmorphic features.
During her first day of life, she presented tremors associ-
ated with severe hypoglycemia (21 mg/dL) that did not
respond to orally given glucose. She presented respiratory
distress that required mechanical ventilation and a septic
shock, which at first misled the clinician about etiology of
hypoglycemia. The severe hypoglycemia persisted in spite
of greater doses of enteral and intravenously glucose
(maximum administration of glucose: 8.5 mg/kg/min). The
situation persisted even after the resolution of neonatal
infection and with normal insulin levels. Moreover, the
baby initially presented non-cholestatic jaundice that was
treated with phototherapy, but she later developed chole-
static jaundice with increased hepatic cytolytic enzymes.
At first, to exclude a metabolic disease, specific tests were
performed resulting in evidence of high glycine levels
(962 lmol/L, normal range 185–767 lmol/L) with no clear
pathologic significance. Endocrinological investigations
were done by the 28th day of life, only after the negativity
of metabolic investigations. Hormonal levels (specified in
Table 1) were evaluated during hypoglycemia and we
found severe combined pituitary hormone deficiency.
Replacement therapy at beginning with hydrocortisone
25 mg/m2 then gradually reduced to 20 mg/m2 three times
a day (at 30 days of life), afterwards also with L-thyroxin
25 lg daily (at 33 days of life) resulted in the complete
resolution of hypoglycemia and the progressive disap-
pearance of cholestatic jaundice. GH therapy was started
later, at 60 days of life. An MRI at 34 days of life allowed
us to confirm the diagnosis of congenital hypopituitarism.
In particular, the MRI showed aplasia of the anterior
pituitary with the absence of PSA and EPP.
Genetic analysis was performed for the HESX1, GLI2
and LHX4 genes, but no mutations have been detected in
these genes.
The child is now 1 year old, presents medium mental
retardation, maintains good control of her hormonal profile
and shows satisfactory growth.
Patient 2
This patient was a male newborn of African origin. He was
born at term by vaginal delivery after an uneventful preg-
nancy. The parents were not related. Apgar score was 10 at
the 1st min and 10 at the 5th min. He did not show signs of
perinatal distress. Birth weight was 2,670 g (-1.64 SD)
and length 49 cm (-0.50 SD). He did not present evident
dysmorphic features. He was dismissed from the birth
hospital on his third day of life with a weight of 2,570 g
and was breastfeeding. That same evening he was brought
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to the emergency department (ED) of our hospital because
he was lethargic and totally refused to eat. In ED, the
newborn appeared severely lethargic, with hypotonia and
hyporeactivity; his glycemia was 7 mg/dL. Routine gly-
cemic checks showed that asymptomatic hypoglycemia
persisted in spite of high doses of enteral and intravenously
given glucose. Moreover, on examination, micropenis with
normal testis was observed. Endocrinological investiga-
tions were performed by the 18th day of life. Hormonal
levels were evaluated during hypoglycemia showing insu-
lin in the normal range but there was a deficiency of
ACTH, cortisol and GH. Replacement therapy beginning
with hydrocortisone 20 mg/m2 three times a day (at
23 days of life) did not resolve the asymptomatic hypo-
glycemia. Moreover, the infant presented progressive
cholestatic jaundice with an important increase in hepatic
enzymes (AST 656 U/L, ALT 300 U/L). Then, metabolic
tests were performed with an initial suspect of galacto-
semia. Therefore, milk feeding was suspended and more
specific metabolic tests were run. These tests definitively
excluded a metabolic disease and MRI (at 33 days of life)
confirmed the endocrinological suspicion of congenital
hypopituitarism by revealing adenohypophysis hypoplasia
with PSA and EPP. GH therapy was started at 52 days of
life with a slight improvement in glycemic control, which
was further improved after increasing hydrocortisone doses
up to 30 mg/m2 three times a day. The hepatic alterations
persisted (AST 443 U/L, ALT 250 U/L) and allowed us to
establish the diagnosis of congenital CMV infection. It was
treated with ganciclovir with an improvement of hepatic
enzymes.
The child is now 1 year old, presents normal develop-
ment and growth, with good control of his hormonal profile
and an important reduction of hydrocortisone requirements
(18 mg/m2). Thyroid functions are still in the normal
range. The micropenis was treated with testosterone 25 mg
every 28 days for 3 times with a good increase in the penile
size.
Genetic analysis was performed for the HESX1 and
LHX4 genes, but no mutations have been detected in these
genes.
Patient 3
This patient was a female newborn of Caucasian origin.
She was born at term by inducted vaginal delivery after an
uneventful pregnancy. The parents were not related. She
had no signs of perinatal distress. Birth weight was 2,820 g
(-0.98 SD) and birth length 48 cm (-0.78 SD). She did
not present evident dysmorphic features. On the second day
of life, she presented severe hypoglycemia that responded
to intravenous glucose. No specific diagnosis was formu-
lated and the newborn was dismissed from the birth
hospital in fifth day of life. At 8 months of life, she was
referred for medical attention due to growth impairment.
Initial tests excluded malabsorption and did not show
evidence of any other disease. At 20 months of life, she
presented severe growth retardation with short stature
(-5.23 SD), had a language delay and was unable to stand.
Endocrine tests showed: GH peak of 0.1 lg/L after insulin
stimulation, nocturnal GH mean of 0.5 lg/L, IGF1
0.39 nmol/L, ACTH, cortisol (basal and peak after insulin
stimulation) and thyroid function were normal, but she
presented a delayed bone age of 16 months. GH therapy
was started at 22 months of life and had a good response.
After the begin of GH therapy, she was submitted to
periodic evaluation of thyroid and adrenal functions; both
remained in the normal range.
An MRI, performed at 23 months of life, showed
hypoplasia of the anterior pituitary, PSA and hypoplasia
and EPP at the level of the floor of the third ventricle.
Moreover, she presented a Chiari 1 malformation. Her
neurological development was evaluated from pediatric
neuropsychiatry which still has in charge of the child. At
the moment, a correlation between her developmental
delay and the diagnosis of hypopituitarism is not found.
The child is now 4 year old, presents a slight develop-
mental delay, and has satisfactory growth thanks to GH
replacement treatment.
Patient 4
This patient was a male newborn of Caucasian origin. He
was born at term by Caesarean delivery after an uneventful
pregnancy. The parents were not related. He did not show
signs of perinatal distress. Birth weight was 4,120 g
(1.66 SD), length 53 cm (1.50 SD). He did not present
evident dysmorphic features. On the second day of life, he
presented generalized seizures associated with severe
hypoglycemia (13 mg/dL) that responded to intravenous
glucose, which was continued for 4 days. At 3 days of life,
he presented jaundice that was treated with phototherapy.
No specific diagnosis was formulated and the newborn was
dismissed from the birth hospital. There were no other
signs or symptoms until 12 months of life, when the baby
had another seizure during a respiratory infection with
fever and refusal of food. Also in this case, the child was in
hypoglycemia (11 mg/dL). Moreover, he presented keton-
uria; consequently, he underwent tests to evaluate the cause
of hypoglycemia but lactic acid, ammonia, insulin, plasma
and urine amino acids, liver function, lipid profile, CPK,
cortisol after ACTH test and GH peak after glucagon
stimulation were all normal. Later, he had two other epi-
sodes of symptomatic hypoglycemia during intercurrent
infections, so at 4 year old he was hospitalized in a Pedi-
atric Metabolic Unit to identify a metabolic disease that
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had not been confirmed. Nevertheless, the symptomatic
hypoglycemia persisted. At 8 years of age, he showed slow
growth velocity. In particular, his growth velocity gradu-
ally diverged from normal height percentiles presenting
short stature and went from 0.8 SD at 2 year old to
-1.23 SD at 4 year old, to -2.5 SD at 8 year old.
Therefore, he underwent to endocrine tests that showed:
GH peak of 0.4 lg/L after arginine stimulation, GH peak
of 0.3 lg/L after clonidine stimulation, IGF1 1.83 nmol/L,
normal ACTH and cortisol functions (after low-dose
ACTH test), and he presented a delayed bone age of
2 years and 6 months. In addition, he presented central
hypothyroidism with a TSH that was not consensually
increased. MRI showed adenohypophysis hypoplasia and
EPP. At 8 years of age, celiac disease was diagnosed and a
gluten-free diet was started.
The boy is now 10 year old and shows satisfactory
growth thanks to GH replacement treatment, which was
begun when he was 8 year old. After the beginning of GH
therapy, he was submitted to periodic evaluation of adrenal
function that remained in the normal range. Nevertheless,
because of persistent symptomatic hypoglycemia during
infections, since his ninth year of life he has been treated
with hydrocortisone during stress events, with a good
response.
Patient 5
This patient was a male newborn of Caucasian origin. He
was born at term by vaginal delivery after an uneventful
pregnancy. The parents were not related. Apgar score was
9 at the 1st min and 10 at the 5th min. He did not show
signs of perinatal distress. Birth weight was 3,600 g
(0.48 SD), length 51 cm (0.50 SD) and cranial circumfer-
ence 36 cm. He did not present evident dysmorphic fea-
tures. On his first day of life, he had a hypoglycemic crisis
that responded to intravenous glucose. At 2 days of life, he
presented jaundice that was treated with phototherapy. No
specific diagnosis was formulated and the newborn was
normally dismissed from the birth hospital. Later on,
between 3 and 5 years of age he suffered two other
hypoglycemic crises. In these occasions, he was submitted
to different tests to evaluate the cause of the hypoglycemia
but all metabolic tests resulted normal. Moreover, he was
also submitted to the evaluations of thyroid function that
resulted normal. Furthermore, he had shown a growth
impairment since he was 2 year old. At 5year old, after
another episode of hypoglycemia occurred, he was hospi-
talized in a Pediatric Endocrinology Unit. During hospi-
talization, it was found that his growth velocity had
gradually diverged from normal height percentiles pre-
senting severe short stature (-3.38 DS). Therefore, he
underwent to endocrine tests that showed a deficient GH
peak after both arginine and clonidine stimulation; very
low IGF1, normal ACTH, cortisol (during hypoglycemia)
and thyroid functions, and a delayed bone age of 3 years.
MRI revealed adenohypophysis hypoplasia, PSA and EPP.
During follow-up, he presented central hypothyroidism
with a TSH value that was not consensually increased, so
replacement therapy with L-thyroxin was started at 7 years
of age. The child is now 8 year old, presents normal
development and a satisfactory growth thanks to GH
replacement treatment, which was started at 5 years of age.
After the beginning of GH therapy, he was submitted to
periodic evaluation of adrenal function that remained in the
normal range.
Discussion
This brief report summarizes the signs and symptoms that
permit to diagnose a congenital hypopituitarism with the
aim to reduce the time for diagnosis and to be able to begin
precocious and appropriate treatment.
In all five cases, the first sign of the disease was early
and severe neonatal hypoglycemia that did not respond to
glucose administration. In four cases, there was jaundice
associated to the hypoglycemia so the clinicians hypothe-
sized a metabolic disease as the first cause of their symp-
toms and delayed the endocrinological tests. Early
diagnosis of hypopituitarism in the neonatal period is dif-
ficult because other factors like neonatal infection and
respiratory distress can confuse the clinical condition, as
for patient 1 [2, 7, 8]. In fact, both birth asphyxia and
perinatal stress produce hyperinsulinism as a consequence
of the use of anaerobic metabolism to maintain blood
glucose concentrations [18]. Therefore, a correct diagnosis
of congenital hypopituitarism is made in the neonatal
period in only 23 % of cases [19]. Nevertheless, in two out
of our five patients with neonatal hypoglycemia, the
diagnosis was confirmed by MRI within the 34th day of
life, and treatment was started in both cases within the 30th
day of life.
Although hypoglycemia represents a common metabolic
issue facing both healthy and ill-appearing neonates, if the
symptoms persist it is necessary to determine the under-
lying cause [20, 21]. Neonatal hypoglycaemia that persists
or recurs after the first few days of life raises the diagnostic
possibility of inborn error of metabolism or of an endocrine
disorder. A wide range of rare metabolic disorders can
present with neonatal hypoglycaemia, among which: con-
genital hyperinsulinism, the most severe and frequent form;
glyco/gluconeogenesis defects; mitochondrial fatty acid
oxidation disorders and some defects in amino acid
metabolism. Furthermore, some of these conditions can
cause liver failure [22, 23].
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On the contrary, hypoglycemia secondary to endocrine
deficiencies is uncommon [24] but no less severe, conse-
quently endocrine evaluations are as necessary as meta-
bolic investigations. In fact, recent research has shown a
death rate of 1 per 31–54 patients-years in children
\6 years of age with a history of hypoglycemia attribut-
able to adrenal insufficiency [25]. Moreover, in England,
Canada and USA, 12–25 % of all deaths in children with
hypothalamic–pituitary disease were due to hypoglycemia
and/or central adrenal insufficiency [26–28]. In our cases,
an indication for an endocrine disorder was the presence of
jaundice in association with the hypoglycemia. In fact, if
one or the other of these symptoms may rarely be involved
in the diagnosis of congenital hypopituitarism, when both
are present, this diagnosis must be rapidly hypothesized
[29]. Indirect hyperbilirubinemia may be caused by thy-
roxine deficiency that prevents bilirubin conjugation [30].
Cholestasis seems to be due to hypocortisolism because
cortisol modulates bile flow and bile acid synthesis. But it
has been hypothesized that even GH is also involved in the
pathogenesis of this disorder since it seems to modulate the
biosynthesis and secretion of biliary acids [7, 31]. From a
clinical point of view, the MPHD has to be considered
responsible for the liver failure presented in different ways
by the patients, as shown by the fact that the hydrocorti-
sone alone does not always resolve the symptomatology,
whereas patients often require GH, as for our patient 2 [7,
30]. However, there is no biochemical alteration of hepatic
dysfunction that is pathognomonic of congenital hypopi-
tuitarism, and in all cases the symptoms regressed with
hormone replacement therapy within 6–10 weeks [31–33].
The difficulty in normalizing liver function in case 2 was
probably due to the presence of a concomitant CMV
infection which complicated the diagnosis and treatment,
prolonging recovery. It is known that congenital CMV
infections are not very frequent but may cause progressive
liver disease, cirrhosis and even death [34].
Another diagnostic difficulty derives from the lack of
established hormonal investigations that would help in
identifying congenital hypopituitarism in the newborn
period [2, 9]. Consensus papers on the diagnosis of GH
deficiency (GHD) repeatedly report the lack of an evi-
dence-based approach to the diagnosis of GHD in the
newborn. In the neonatal period, the diagnosis can be
classically made on the basis of a GH level \20 lg/L
during hypoglycemia or after a glucagon stimulation test
[35]; but, in the presence of clinical evidence, the diag-
nosis of severe neonatal GHD can be confirmed during
the first week of life by a single randomly taken GH level
of less than 7 lg/L [36]. Patients 1 and 2 both presented a
basal GH level under 3 lg/L during hypoglycemia, so the
diagnosis could already be hypothesized after this blood
exam.
In both these cases, the GH treatment was started rela-
tively early, within 2 months of life. This was necessary in
patient 2 because the GH therapy was essential in main-
taining the glycemia in the normal range. Moreover, lit-
erature suggests that in suspected cases of neonatal GHD,
independently from neonatal symptoms, GH therapy
should be started immediately [36]. It is known, in fact,
that if children with congenital hypopituitarism are usually
of normal or moderately reduced size and weight at birth,
there is a rapid growth impairment in the first months of
life [5]. Consequently, children with untreated GHD are
often more than 4 SD below the mean by 1 year of age and
achieve only 70 % of their full growth potential. As a
consequence, they present a deficit on average of 38 cm in
males and 33 cm in females. This data emphasize the
importance of early diagnosis and treatment, before the
statural impairment becomes particularly evident [16].
Thanks to early GH treatment, children with hypopituita-
rism present a mean gap between final size and parental
target size of only 0.1 ± 1.1 SD, confirming, therefore,
that early diagnosis and treatment are essential in this
setting [37].
After the beginning of GH treatment, particular attention
has to be paid to thyroid and cortisol function. Some
patients, in fact, develop either primary or central hypo-
thyroidism while treated with GH. Similarly, there is a risk
of developing adrenal insufficiency that, if unrecognized,
can be fatal. Periodic evaluation of thyroid and adrenal
function is therefore indicated for all patients treated with
GH [16].
Thyroid function was assessed and revealed central
hypothyroidism in patients 1, 4 and 5: all of them at first
investigation presented low FT4 with a TSH not consen-
sually increased. This is not an innovative result because
other authors have described this phenomenon as probably
due to the presence of some thyrotropin-producing cells [7,
38, 39]. On the contrary, patients 2 and 3 still have normal
thyroid function.
In both, patients 1 and 2, we started replacement therapy
with hydrocortisone as soon as possible to avoid the severe
hypoglycemia that occurred in the first days of life. We
used a high dose of hydrocortisone to prevent hypoglyce-
mia, in particular in patient 2 who also needed GH treat-
ment to normalize his glycemia. In both, the doses were
progressively reduced. The use of large doses of a fat-
soluble hormone as hydrocortisone has been previously
described during cholestasis because in this condition,
there is an insufficiency of bile acids secretion in the
intestine and consequently, a difficulty for the absorption of
fat-soluble substances [40].
Patient 2, also, presented a micropenis that was recog-
nized only at the readmission to the hospital because of a
severe hypoglycemia. Micropenis may often be the first
1206 J Endocrinol Invest (2014) 37:1201–1209
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clinical sign to suspect a congenital hypopituitarism, as in
this case. In utero, in fact, penis growth is consequent to
androgens produced by fetal pituitary gonadotropins; con-
sequently, micropenis in a newborn often suggests a defect
in some component of the hypothalamic–pituitary–gonadal
axis during fetal development. Therefore, it is essential that
it is recognized as quickly as possible so that an appropriate
treatment can be started to minimize medical and psy-
chological complications [41]. About the therapy of
micropenis in congenital hypopituitarism, there are differ-
ent positions: some authors reported that a considerable
growth of the penile size may be obtained with GH
replacement therapy, indirectly emphasizing the impor-
tance of precociously starting GH therapy [42]; others
underline the necessity of testosterone administration to
increase the penis size [7, 43]. Finally, some authors have
recently suggested that the use of recombinant human FSH
and LH injections during the neonatal period showed
encouraging results in improving sexual and reproductive
functions in adulthood [44].
In three of our cases, the diagnosis was made after the
neonatal period, respectively, at 2, 8 and 5 years of life. In
all patients, the hypoglycemic symptoms present at birth
were not appropriately investigated and later on for patients
4 and 5, the metabolic investigations were preferred to
endocrinological tests. Therefore, the definitive diagnosis
was delayed. In all three cases, the main clinical sign was
severe growth impairment. These different clinical presen-
tations of the same condition underline that hypopituitary
phenotypes can be highly variable and can evolve over time
[2]. In this contest, it is necessary to evaluate the pituitary–
adrenal function. In fact, it is described that patients with
GHD and EPP, as all these three children, developed a
central adrenal insufficiency within 2 years of follow-up
[45]. If an overt adrenal failure is easily discernible, the
detection of asymptomatic children with a subtle dysfunc-
tion of the pituitary–adrenal axis is still a difficult diagnosis.
Nowadays, the reference test for the diagnosis is considered
the insulin tolerance test [46] that was performed in patient
3. Nevertheless, recent data identified the low-dose ACTH
test as useful in the study of the integrity of the pituitary–
adrenal axis in children older than 3 years. Moreover, the
usefulness of this test should be higher than the standard
dose ACTH test, for this group of children [46]. Because
patient 4 was submitted to GH stimulating tests in another
hospital where the insulin tolerance test was not used, we
preferred to use the low-dose ACTH test to evaluate the
pituitary–adrenal function. On the contrary, for patient 5,
the normality of ACTH and cortisol during hypoglycemia
allowed us to avoid the stimulating test, for the evaluation
of adrenal–pituitary axis.
The diagnosis was definitively confirmed in all cases by
MRI. MRI patterns have important clinical interpretation
for both treatment and follow-up. In fact, in one study after
a mean follow-up period of 4.5 years, 5.4 % of subjects
with isolated GHD and abnormal MRI progressed to
MPHD, while none of those with normal MRI progressed
[47]. Moreover, the identification of a particular MRI
phenotype is also helpful in terms of genetic counselling,
though none of our patients present, at the moment, con-
firmed genetic alteration as the cause of their MRI phe-
notype [8, 10]. Since the evolution of the disease can
possibly involve other pituitary hormone deficiencies over
time, genetic analysis should also be taken into account for
the future follow-up of these patients, including other
candidate genes [15–17].
A correlation between EPP and stalk abnormality and
MPHD has been described; these patients in particular have
shown GHD, hypocortisolism and hypothyroidism [47].
Whereas patient 1 had alterations of all three axes, patient 2
presented only the alteration of the GH and cortisol axes and
patients 4 and 5 only of the GH and thyroid axes. They are
again, most likely, too young to present the other hormone
deficiencies and a strict, lifelong follow-up will be neces-
sary to evaluate their clinical evolution. In fact, as men-
tioned above, the clinical presentation of pituitary hormone
disease may be dynamic because subsequent additional
hormone deficiencies may develop over time [48].
In conclusion, the clinical phenotype of congenital
hypopituitarism is highly variable and consequently the
definitive diagnosis is often delayed. In fact, in four out of
five our cases, the clinical signs suggested a metabolic
disorder which initially misled the clinician regarding the
etiology of the children’s clinical condition. We would like
to emphasize the importance of suspecting congenital
hypopituitarism in the presence of severe and persistent
neonatal hypoglycemia associated with cholestatic jaun-
dice and in childhood in the presence of a precocious
reduction of growth velocity that gradually diverges from
normal height percentiles presenting severe short stature.
In all such cases, it is necessary to carry out as soon as
possible the investigations necessary for the diagnosis, in
particular a hypothalamic–pituitary MRI scan, and finally
to start the appropriate treatment as soon as possible.
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